Market Overview

The Buck Institute, Insilico Medicine, and Juvenescence Found Napa Therapeutics to Develop Drugs to Impede Age-Related Disease


Collaboration will harness AI technology to address an aging-related

Buck Institute for Research on Aging,
, and Juvenescence
announced today that they have formed Napa Therapeutics, Ltd to
develop drugs against a novel aging-related target. The Buck Institute
is one of the leading research centers in the world focused solely on
research on aging and the elimination of age-related disease. Insilico
Medicine is an AI company focused on a range of verticals devoted to
aging. Insilico Medicine stands to earn more than $100M in milestone
payments should the program be successful. Juvenescence is a company
focused on developing drugs to modify aging and the diseases of aging.

Napa Therapeutics is based on groundbreaking research in NAD metabolism
conducted in the lab of Eric Verdin, MD, President and CEO of the Buck
Institute. The Verdin
will collaborate with Napa, using Insilico's drug development
engine to speed the discovery of new compounds. "This is a unique
opportunity to use cutting-edge AI to accelerate drug discovery," said
Dr. Verdin. "The Buck is excited to join forces with Insilico and
Juvenescence as we work to eliminate the threat of age-related disease
for this and future generations."

"I am most excited by this model and the ability to combine the quality
science of the Buck Institute with the remarkable deep learning engine
at Insilico Medicine. To me this is another big step in the evolving
process of using AI with HI (human intelligence) to extract the best of
both systems," said Gregory Bailey, MD, CEO of Juvenescence. "Napa
Therapeutics lets Juvenescence deepen our collaboration with the Buck
Institute and with Insilico Medicine. We hope to shorten the time
required to identify molecules that can be brought to the clinic and
most importantly help patients."

"We are very happy to partner with the Buck Institute and Juvenescence
around a very promising set of targets in a pathway overlooked by the
pharmaceutical industry. Aging research is among the most altruistic
causes that will improve and extend the lives of everyone on the planet
and reduce the pain and suffering associated with the age-associated
diseases. However, in order to scale, our efforts must become
sustainable and provide reasonable returns to investors. If successful,
Insilico Medicine alone stands to earn in excess of $100 million in
milestone payment from this deal", said Alex Zhavoronkov, PhD, founder
and CEO of Insilico Medicine.


About Napa Therapeutics. Ltd

Napa Therapeutics, Ltd. is a biotechnology company focused on a novel
target linked to one of the fundamental processes of aging. A privately
held British Virgin Islands company with an office in the Isle of Man,
Napa is developing small molecule drugs to address this target.

About the Buck Institute for Research on Aging

Our success will ultimately change healthcare. At the Buck, we aim to
end the threat of age-related diseases for this and future generations
by bringing together the most capable and passionate scientists from a
broad range of disciplines to identify and impede the ways in which we
age. An independent, nonprofit institution, our goal is to increase
human health span, or the healthy years of life. Globally recognized as
the pioneer and leader in efforts to target aging, the number one risk
factor for serious diseases including Alzheimer's, Parkinson's, cancer,
macular degeneration, heart disease, and diabetes, the Buck wants to
help people live better longer. Learn more at:

About Juvenescence, Ltd.

is a company focused on developing therapies and drugs to
increase human longevity and complementary investments in related
sectors. It was founded in 2017. The Juvenescence team are highly
experienced entrepreneurs and drug developers focused on life science
and commercial drug development. Juvenescence creates new ventures and
invests time and money directly in both start-up and in conjunction with
established longevity related companies offering operational support.

Juvenescence believes that advances in science have made real the
possibility of slowing, halting or potentially reversing some elements
of ageing and is assembling a pipeline of therapeutic agents through
joint ventures.

About Insilico Medicine, Inc.

is an artificial intelligence company with R&D offices and
resources in the US, Belgium, Russia, the UK, Taiwan and Korea, sourced
through hackathons and competitions. The company and its scientists are
dedicated to extending human productive longevity and transforming every
step of the drug discovery and drug development process through
excellence in biomarker discovery, drug development, digital medicine
and aging research.

Insilico pioneered the applications of the generative adversarial
networks (GANs) and reinforcement learning for generation of novel
molecular structures for diseases with a known ligand and with no known
targets. In addition to working collaborations with large pharmaceutical
companies, the company is pursuing internal drug discovery programs in
cancer, dermatological diseases, fibrosis, Parkinson's Disease,
Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a
partnership with the company launched a range of
nutraceutical products, compounded using advanced bioinformatics and
deep learning techniques. It also provides a range of consumer-facing
applications, including Young.AI.

In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI
companies for potential in social impact. In 2018, the company was named
one of the global top 100 AI companies by CB Insights. In 2018 it
received the Frost & Sullivan 2018 North American Artificial
Intelligence for Aging Research and Drug Development Award accompanied
by industry brief. Brief company video:

View Comments and Join the Discussion!